These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34088709)

  • 1. Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests.
    Rhodes FA; Cococcia S; Patel P; Panovska-Griffiths J; Tanwar S; Westbrook RH; Rodger A; Rosenberg W
    BMJ Open; 2021 Jun; 11(6):e047786. PubMed ID: 34088709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    Srivastava A; Gailer R; Tanwar S; Trembling P; Parkes J; Rodger A; Suri D; Thorburn D; Sennett K; Morgan S; Tsochatzis EA; Rosenberg W
    J Hepatol; 2019 Aug; 71(2):371-378. PubMed ID: 30965069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients.
    Broussier T; Lannes A; Zuberbuhler F; Oberti F; Fouchard I; Hunault G; Cales P; Boursier J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):349-355. PubMed ID: 31422033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and the interface between primary and secondary care.
    Tsochatzis EA; Newsome PN
    Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):509-517. PubMed ID: 29893235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying High-Risk Patients With Nonalcoholic Fatty Liver Disease: An Opportunity for Intervention Within the Primary Care Setting.
    No JS; Buckholz A; Han C; Matthews S; Fortune B; Krisko T; Newberry C; Kumar S
    J Clin Gastroenterol; 2023 Oct; 57(9):956-961. PubMed ID: 36731002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD.
    Ciardullo S; Ronchetti C; Muraca E; Oltolini A; Perra S; Bianconi E; Zerbini F; Cannistraci R; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    J Endocrinol Invest; 2020 Jul; 43(7):1019-1026. PubMed ID: 32008185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis.
    Crossan C; Majumdar A; Srivastava A; Thorburn D; Rosenberg W; Pinzani M; Longworth L; Tsochatzis EA
    Liver Int; 2019 Nov; 39(11):2052-2060. PubMed ID: 31332938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016.
    Ciardullo S; Sala I; Perseghin G
    Diabetes Res Clin Pract; 2020 Sep; 167():108358. PubMed ID: 32745698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
    Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
    Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local care and treatment of liver disease (LOCATE) - A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care.
    El-Gohary M; Moore M; Roderick P; Watkins E; Dash J; Reinson T; Newell C; Kim M; Stuart B; Becque T; Sheron N
    PLoS One; 2018; 13(12):e0208798. PubMed ID: 30576330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.
    Gracen L; Hayward KL; Aikebuse M; Russell A; O'Beirne J; McPhail S; Irvine KM; Williams S; Valery PC; Powell EE
    BMC Health Serv Res; 2022 Apr; 22(1):487. PubMed ID: 35413987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients.
    Fox RK; Chu JN; Goldman ML; Islam KB; Brandman D
    Hepatol Commun; 2023 Feb; 7(2):e0024. PubMed ID: 36724121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
    Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
    PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.